Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric Asthma (US)
Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as Ventolin HFA) and maintenance therapy to prevent exacerbations by targeting the underlying pathophysiology (e.g., a LABA / ICS such as GSK’s Advair, an anti-IL-5 agent such as AstraZeneca’s Fasenra). Many pediatric patients receive combination regimens to achieve adequate disease control. Despite the availability of multiple well-established therapies, additional agents have been approved and launched in recent years, including novel biologics (e.g., Regeneron / Sanofi’s Dupixent) and generic versions of blockbuster inhaled drugs (e.g., albuterol sulfate, salmeterol / fluticasone propionate). These developments have expanded treatment options and increased the competition within the pediatric asthma market.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric asthma patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric asthma patients?
- How has AstraZeneca’s Tezspire been integrated into the treatment algorithm, and what is its source of business?
- What percentage of pediatric asthma patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of pediatric asthma patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Geography: United States
Key drugs: Advair, Symbicort, Breo, Dupixent, Fasenra, Nucala, Xolair, Tezspire, Spiriva, montelukast sodium, fluticasone propionate
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
PRODUCT ENHANCEMENT
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
KEY FEATURE
Dashboard featuring interactive visuals, easy navigation, and expanded analyses
